Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression
1 Department of Neurosciences, Imaging and Clinical Sciences, University "G. D'Annunzio", Chieti, Italy.
2 Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
3 VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, Connecticut, USA.
4 Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, Connecticut, USA.
5 Chair of Psychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
6 IRCCS Fondazione Santa Lucia, Rome, Italy.
7 Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
8 Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
9 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
10 Braxia Health, Canadian Centre for Rapid Treatment Excellence (CRTCE), Mississauga, Ontario, Canada.
11 Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
12 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.